24 results
Thumbnail

D1.172 - Parallel Trajectories of Lung Function and Allergic Sensitization in Childhood Asthma: A 7-Year Prospective Study

Thumbnail

D1.180 - Hidden fragility behind optimal ACT score: identifying silent-risk phenotypes through clinical-biological dissociation

Thumbnail

D1.182 - Relationship between eHealth Literacy and Medication Adherence in Patients with Asthma: The Mediating Role of Self-Efficacy

Thumbnail

D1.171 - Real-World Exacerbation Outcomes After AIR Therapy Rescue Implementation: Toward a SABA-Free Era

Thumbnail

D1.173 - Sputum Tryptase Identifies Airway Mast Cell Activation Across Asthma Phenotypes

Thumbnail

D1.174 - Framing ADAM17 alterations across bronchial, sputum and nasal sites in asthma and controls

Thumbnail

D1.175 - Clinical Phenotypes of Difficult-to-treat and Mild Asthma Defined by Cluster Analysis

Thumbnail

D1.176 - Prognostic Evaluation of the Allergic March in Patients with Atopic Dermatitis

Thumbnail

D1.177 - Turkish Validity and Reliability of the Medication Adherence Report Scale for Asthma (MARS-A) in Adolescents with Asthma

Thumbnail

D1.178 - Real-World Comparison of Inhaled Corticosteroid Monotherapy versus Fixed-Dose Inhaled Corticosteroid–Long-Acting Beta-2 Agonist Combinations in Children Aged 6–11 Years with Persistent Asthma

Thumbnail

D2.449 - Patients with Inadequately Controlled CRSwNP and Blood Eosinophil Count ≥150 cells/µL Experience Benefit with Depemokimab: An Analysis of Data from the Integrated ANCHOR-1/-2 Studies

Thumbnail

D2.447 - Phenotyping of Chronic T2 Inflammatory Diseases of the Nose and Paranasal Sinuses and the Algorithm for Biologic Therapy Selection

Thumbnail

D2.448 - Recommendations on Patient Education for Biological Therapy in CRSwNP – An EAACI Position Paper

Thumbnail

D2.450 - EUFOREA/EPOS Criteria Applied to a Diverse CRSwNP Cohort: Post Hoc Findings from Twice-Yearly depemokimab ANCHOR-1/-2 trials

Thumbnail

D2.451 - Real-life upper and lower airway outcomes of long-term dupilumab treatment in patients with severe chronic rhinosinusitis with nasal polyps

Thumbnail

D2.452 - Real-World Trends in the Epidemiology and Burden of Chronic Rhinosinusitis with Nasal Polyps Over Time in Germany Reveal Increasing Prevalence and Low Biologic Use

Thumbnail

D2.453 - Olfactory outcomes of dupilumab in patients with CRSwNP: A real-world prospective study

Thumbnail

D2.455 - Does Biological Therapy Modify NSAID Hypersensitivity? Experience with Omalizumab and Mepolizumab in Patients with Asthma and Nasal Polyps with N-ERD

Thumbnail

D2.456 - Chronic sinusitis with nasal polyposis: Add-on aspirin desensitization useful in dupilumab therapy?

Thumbnail

D2.457 - Hypersensitivity reactions for Enzyme Replacement Therapy in a Patient with Hunter syndrome